• Aliases: AZD 2171, Recentin (tentative trade name)
    • Highly potent VEGFR inhibitor, which may inhibit VEGF-A)–driven angiogenesis
    • Phase 3 clinical trials with recurrent glioblastoma ongoing; currently under investigation in phase 2 clinical trials for newly diagnosed glioblastoma, thyroid cancer, and ovarian and triple-negative breast cancer
    • Recommended phase 2 dose: 30 or 45 mg orally daily (20 mg when combined with cytotoxic chemotherapy)
    • Half-life: â™22 hours
    • Common side effects: Fatigue, diarrhea, nausea, dysphonia, hypertension (proteinuria)
    (Drevs et al., 2007; Ryan et al., 2007)
    Other topics in Targeted and Immunotherapy Agents